LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・Kura Oncology Inc

Kura Oncology Inc

Abrir

SetorSaúde

11.14

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

11.06

Máximo

11.39

Indicadores-chave
By Trading Economics
Rendimento	7.7M -73M
Vendas	929K 18M
Margem de lucro	-401.495
Funcionários	260
EBITDA	7.4M -78M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+149.87% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-31M 813M
Abertura anterior	11.14
Fecho anterior	11.14

Sentimento de Notícias

By Acuity

50%

151 / 345 Ranking em Healthcare

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de mai. de 2026, 23:46 UTC

Conversa de Mercado

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 de mai. de 2026, 23:42 UTC

Conversa de Mercado

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 de mai. de 2026, 23:11 UTC

Conversa de Mercado

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 de mai. de 2026, 22:26 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 de mai. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 de mai. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 de mai. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 de mai. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 de mai. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 de mai. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 de mai. de 2026, 22:11 UTC

Conversa de Mercado

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 de mai. de 2026, 22:04 UTC

Conversa de Mercado

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

23 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 de mai. de 2026, 21:10 UTC

Ganhos

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de mai. de 2026, 19:47 UTC

Ganhos

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 de mai. de 2026, 19:17 UTC

Conversa de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 de mai. de 2026, 19:10 UTC

Conversa de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 de mai. de 2026, 18:38 UTC

Conversa de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 de mai. de 2026, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 de mai. de 2026, 18:09 UTC

Conversa de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 de mai. de 2026, 17:58 UTC

Conversa de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

149.87% parte superior

Previsão para 12 meses

Média 28.11 USD 149.87%

Máximo 40 USD

Mínimo 15 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Kura Oncology Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

151 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.